Enovis Corporation ENOV 深 滬
等待開盤 06-25 09:30:00 美东时间
21.38
+0.230
+1.09%
華盛通- 最 高21.98
- 今 開21.27
- 成交量 122.55万股
- 最 低 21.18
- 昨 收 21.15
- 總市值 12.31亿
- 52周最高 36.82
- 市盈率 靜 --
- 換手率 2.13%
- 52周最低 20.55
- 委 比 0.00%
- 總股本 5756.26万
- 歷史最高 176.11
- 量 比 1.03
- 振 幅 3.78%
- 歷史最低 -13.31
- 每 手 1
- 風險率 3.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Enovis Chief Administrative Officer Oliver Engert acquires 1,200 common shares for $26,448
Enovis Chief Administrative Officer Oliver Engert acquires 1,200 common shares for $26,448 Enovis Chief Administrative Officer Oliver Engert bought 1,200 common shares in open-market purchases at USD 20.99 to USD 21.75 each. Engert’s direct holding rose to 51,840 shares following the transactions. D
06-16 09:00
BTIG Reiterates Buy on Enovis, Maintains $39 Price Target
BTIG analyst Ryan Zimmerman reiterates Enovis (NYSE:ENOV) with a Buy and maintains $39 price target.
05-22 20:11
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Wells Fargo Maintains Overweight on Enovis, Lowers Price Target to $40
Wells Fargo analyst Larry Biegelsen maintains Enovis (NYSE:ENOV) with a Overweight and lowers the price target from $42 to $40.
05-08 21:24
财报速睇 | Enovis Corporation 2026财年Q2营收5.89亿美元，同比增长5.4%；归母净利润亏损0.09亿美元，同比亏损缩窄84.3%
华盛资讯5月7日讯，Enovis Corporation公布2026财年Q2业绩，公司Q2营收5.89亿美元，同比增长5.4%，归母净利润亏损0.09亿美元，同比亏损缩窄84.3%。
05-07 18:51
财报速睇 | Enovis Corporation 2026财年Q2营收5.89亿美元，同比增长5.4%；归母净利润亏损0.09亿美元，同比亏损缩窄84.3%
华盛资讯5月7日讯，Enovis Corporation公布2026财年Q2业绩，公司Q2营收5.89亿美元，同比增长5.4%，归母净利润亏损0.09亿美元，同比亏损缩窄84.3%。
05-07 18:47
Enovis Corporation beats Q1 street estimates
Enovis Corporation press release (ENOV): Q1 Non-GAAP EPS of $0.89 beats by $0.08. Revenue of $589M (+5.4% Y/Y) beats by $16.56M. Enovis reaffirms financial expectations for 2026. Revenue is expected t...
05-07 18:16
Enovis Affirms FY2026 Adj EPS Guidance of $3.52-$3.73 vs $3.62 Est; Affirms FY2026 Sales Guidance of $2.310B-$2.370B vs $2.344B Est
Enovis (NYSE:ENOV) affirms FY2026 Adj EPS guidance from $3.52-$3.73 to $3.52-$3.73 vs $3.62 analyst estimate. Affirms FY2026 sales outlook from $2.310 billion-$2.370 billion to $2.310 billion-$2.370 billion vs $2.344
05-07 18:08
Enovis Q1 Adj. EPS $0.89 Beats $0.82 Estimate, Sales $589.200M Beat $571.131M Estimate
Enovis (NYSE:ENOV) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.82 by 8.54 percent. This is a 9.88 percent increase over earnings of $0.81 per share from the same period
05-07 18:07
Compex begins multi-year supplier partnership with Chelsea FC Women
Compex begins multi-year supplier partnership with Chelsea FC Women Compex, part of Enovis, entered multi-year supplier partnership with Chelsea FC Women to provide electrical muscle stimulation devices for player recovery, performance support, pain management. EMS technology to be integrated into c
05-05 22:50
